Bausch Health Companies Inc (NYSE:BHC) does about 2.31M shares in volume on a normal day but saw 1137620 shares change hands in Friday trading. The company now has a market cap of 3.49B USD. Its current market price is $9.56, marking an increase of 0.63% compared to the previous close of $9.50. The 52 week high reached by this stock is $10.15 whilst the lowest price level in 52 weeks is $5.57.
Bausch Health Companies Inc (BHC) has a 20-day trading average at $9.35 and the current price is -5.77% off the 52-week high compared with 71.62% distance from its 52-week low. The 50-day simple moving average of the closing price is $8.72 and its 200-day simple moving average is $8.10. If we look at the stock’s price movements over the week, volatility stands at 2.52%, which increases to 3.20% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 62.03 to suggest the stock is neutral.
The consensus objective for the share price is $9.83, suggesting that the stock has a potential upside of 2.75% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on September 20, 2023 when Jefferies upgraded the stock to “Buy” and issued a price target of between $9 and $16.
Bausch Health Companies Inc (BHC) stock is up 3.91% over the week and 2.80% over the past month. Its price is 19.20% year-to-date and 26.12% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/30/2023, with the company’s earnings per share (EPS) of $1.15 above consensus estimates by $0.13. BHC’s earnings per share are forecast to grow by 12.60% this year and 1.50% over next year. Expected sales for next quarter are $2.35 billion, which analysts say will come at $9.39 billion for the current fiscal year and next year at $9.44 billion. In addition, estimates put the company’s current quarterly revenue at an average of $2.15 billion.
To reach the target analysts have set, the stock logically needs to grow 2.75 percent from here.
Outstanding shares total 365.24M with insiders holding 8.18% of the shares and institutional holders owning 81.00% of the company’s common stock. The company has a return on investment of -2.81%. The forward price to earnings ratio is 2.39. The beta has a value of 0.83. Price to sales ratio is 0.40.
